This content is from: Japan

Takeda Pharmaceuticals announces Japan MAP failure

Takeda Pharmaceuticals has announced that its mutual agreement procedure (MAP) with the National Tax Agency in Japan did not result in an agreement with the US.

To access our market-driven intelligence please request a trial here.

Read this article – and more – for a one-week period.


Are you already an ITR subscriber? Log in here

Instant access to all of our content. Membership Options | One Week Trial